154 related articles for article (PubMed ID: 22447019)
1. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial.
Soejima H; Ogawa H; Morimoto T; Nakayama M; Okada S; Uemura S; Kanauchi M; Doi N; Sakuma M; Jinnouchi H; Sugiyama S; Waki M; Saito Y;
Circ J; 2012; 76(6):1526-32. PubMed ID: 22447019
[TBL] [Abstract][Full Text] [Related]
2. Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.
Soejima H; Ogawa H; Morimoto T; Nakayama M; Okada S; Sakuma M; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Waki M; Saito Y;
J Cardiol; 2013 Sep; 62(3):165-70. PubMed ID: 23778008
[TBL] [Abstract][Full Text] [Related]
3. Primary prevention with aspirin in type 2 diabetic patients. Searching for the right spot.
Manzano-Fernández S; Tello-Montoliu A; Marín F
Circ J; 2012; 76(6):1333-4. PubMed ID: 22531598
[No Abstract] [Full Text] [Related]
4. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Saito Y; Morimoto T; Ogawa H; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sugiyama S; Okada S; Akai Y;
Diabetes Care; 2011 Feb; 34(2):280-5. PubMed ID: 21270185
[TBL] [Abstract][Full Text] [Related]
5. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Hansson L
J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
[TBL] [Abstract][Full Text] [Related]
6. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y;
JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial.
Okada S; Morimoto T; Ogawa H; Kanauchi M; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sakuma M; Saito Y;
Diabetes Care; 2011 Jun; 34(6):1277-83. PubMed ID: 21515838
[TBL] [Abstract][Full Text] [Related]
8. Different levels of blood pressure, different benefit from dual antiplatelet therapy in minor stroke or TIA patients.
Xu J; Tao Y; Li H; Gu H; Xie X; Meng X; Xu Y; Wang Y; Wang Y
Sci Rep; 2017 Jun; 7(1):3884. PubMed ID: 28634365
[TBL] [Abstract][Full Text] [Related]
9. The effects of cardiovascular risk factor combined anti-platelet therapy and the risk of cerebrovascular events in patients with T2DM in an urban community over 96-months follow-up: The Beijing communities diabetes study 19.
Zhang XL; Fu HJ; Yang GR; Wan G; Li D; Zhu LX; Xie RR; Lv YJ; Zhang JD; Li YL; Dai QF; Ji Y; Gao DY; Cui XL; Liu DY; Yuan SY; Yuan MX;
Diabetes Res Clin Pract; 2018 Oct; 144():236-244. PubMed ID: 30218743
[TBL] [Abstract][Full Text] [Related]
10. Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients.
Soejima H; Ogawa H; Morimoto T; Okada S; Matsumoto C; Nakayama M; Masuda I; Jinnouchi H; Waki M; Saito Y;
J Cardiol; 2020 Apr; 75(4):387-393. PubMed ID: 31564388
[TBL] [Abstract][Full Text] [Related]
11. Relationships between the risk of cardiovascular disease in type 2 diabetes patients and both visit-to-visit variability and time-to-effect differences in blood pressure.
Takao T; Kimura K; Suka M; Yanagisawa H; Kikuchi M; Kawazu S; Matsuyama Y
J Diabetes Complications; 2015 Jul; 29(5):699-706. PubMed ID: 25861721
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure targets for hypertension in people with diabetes mellitus.
Arguedas JA; Leiva V; Wright JM
Cochrane Database Syst Rev; 2013 Oct; (10):CD008277. PubMed ID: 24170669
[TBL] [Abstract][Full Text] [Related]
13. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
Soejima H; Morimoto T; Saito Y; Ogawa H
Thromb Haemost; 2010 Dec; 104(6):1085-8. PubMed ID: 20941462
[No Abstract] [Full Text] [Related]
14. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study.
Cheng YY; Leu HB; Chen TJ; Chen CL; Kuo CH; Lee SD; Kao CL
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e99-105. PubMed ID: 24119365
[TBL] [Abstract][Full Text] [Related]
15. One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus.
Soejima H; Ogawa H; Morimoto T; Okada S; Sakuma M; Nakayama M; Masuda I; Doi N; Uemura S; Jinnouchi H; Sugiyama S; Waki M; Saito Y;
J Cardiol; 2019 Jan; 73(1):33-37. PubMed ID: 30487058
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients.
Soejima H; Ogawa H; Morimoto T; Okada S; Matsumoto C; Nakayama M; Masuda I; Jinnouchi H; Waki M; Saito Y;
Heart Vessels; 2023 Nov; 38(11):1371-1379. PubMed ID: 37522902
[TBL] [Abstract][Full Text] [Related]
17. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Sacco M; Pellegrini F; Roncaglioni MC; Avanzini F; Tognoni G; Nicolucci A;
Diabetes Care; 2003 Dec; 26(12):3264-72. PubMed ID: 14633812
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Rhee SY; Kim YS; Chon S; Oh S; Woo JT; Kim SW; Kim JW
Diabetes Res Clin Pract; 2011 Jan; 91(1):e11-4. PubMed ID: 20934769
[TBL] [Abstract][Full Text] [Related]
19. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Kjeldsen SE; Berge E; Bangalore S; Messerli FH; Mancia G; Holzhauer B; Hua TA; Zappe D; Zanchetti A; Weber MA; Julius S
Blood Press; 2016; 25(2):83-92. PubMed ID: 26511535
[TBL] [Abstract][Full Text] [Related]
20. ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES.
Foster JG; Wood SK; Pfeffer MA; DeMets DL; Garber A; Hennekens CH
Endocr Pract; 2018 Oct; 24(10):925-927. PubMed ID: 29975578
[No Abstract] [Full Text] [Related]
[Next] [New Search]
